We report a detailed genetic and genomic map of multiple sclerosis, and describe the role of putatively affected genes in the peripheral immune system and brain resident microglia.
Introduction
Over the last decade, elements of the genetic architecture of multiple sclerosis (MS) susceptibility have gradually emerged from genome-wide and targeted studies. (1) (2) (3) (4) (5) The role of the adaptive arm of the immune system, particularly its CD4+ T cell component has become clearer, with multiple different T cell subsets being implicated.(4) While the T cell component plays an important role, functional and epigenomic annotation studies have begun to suggest that other elements of the immune system may be involved as well.(6, 7) Here, we assemble available genome-wide MS data to perform a meta-analysis followed by a systematic, comprehensive replication effort in large independent sets of subjects. This effort has yielded a detailed genomewide genetic map that includes the first successful evaluation of the X chromosome in MS and provides a powerful platform for the creation of a detailed genomic map outlining the functional consequence of each variant and their assembly into susceptibility networks.
Discovery and replication of genetic associations
We organized available (1, 2, 4, 5) and newly genotyped genome-wide data in 15 data sets, totaling 14,802 subjects with MS and 26,703 controls for our discovery study (Supplementary Methods, Supplementary Tables 1-3). After rigorous per data set quality control, we imputed all samples using the 1000 Genomes European panel resulting in an average of 8.6 million imputed single nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) of at least 1% (Supplementary Methods). We then performed a meta-analysis, penalized for within-data set residual genomic inflation, to a total of 8, 278, 136 SNPs with data in at least two data sets (Supplementary Methods). Of these, 26,395 SNPs reached genome-wide significance (p-value < 5x10 -8 ) and another 576,204 SNPs had at least nominal evidence of association (5x10 -8 > p-value < 0.05). In order to identify statistically independent SNPs in the discovery set and to prioritize variants for replication, we applied a genome partitioning approach (Supplementary Methods).
Briefly, we first excluded an extended region of ~12Mb around the major histocompatibility complex (MHC) locus to scrutinize this unique region separately (see below), and we then applied an iterative method to discover statistically independent SNPs in the rest of the genome using conditional modeling. We partitioned the genome into regions by extracting ±1Mbs on either side of the most statistically significant SNP and repeating this procedure until there were no SNPs with a p-value<0.05 in the genome. Within each region we applied conditional modeling to identify statistically independent effects. As a result, we identified 1,961 non-MHC autosomal regions that included 4,842 presumably statistically independent SNPs. We refer these 4,842
prioritized SNPs as "effects", assuming that these SNPs tag a true causal genetic effect. Of these, 82 effects were genome-wide significant in the discovery analysis, and another 125 had a p-value < 1x10 -5 .
In order to replicate these 4,842 effects we analyzed two large-scale independent sets of data.
First, we designed the MS Chip to directly replicate each of the prioritized effects (Supplementary Methods) and, after stringent quality check (Supplementary Methods and   Supplementary Table 4) , analyzed 20,282 MS subjects and 18,956 controls, which are organized in 9 data sets. Second, we incorporated targeted genotyping data generated using the ImmunoChip platform on an additional 12,267 MS subjects and 22,625 control subjects that had not been used in either the discovery or the MS Chip subject sets (Supplementary Table 5) . (3) Overall, we jointly analyzed data from 47,351 MS cases and 68,284 control subjects to provide the largest and most comprehensive genetic evaluation of MS susceptibility to date. Table 6 ). The odds ratios (ORs) of these genome-wide effects ranged from 1.06 to 2.06, and the allele frequencies of the respective risk allele from 2.1% to 98.4% in the European samples of the 1000 Genomes reference (mean: 51.3%, standard deviation: 24.5%;
Supplementary Table 7 and Supplementary Figure 1) . 19 .7% of regions (31 out of 157) harbored more than one statistically independent GW effect. One of the most complex regions was the one harboring the EVI5 gene that has been the subject of several reports with contradictory results. (8) (9) (10) (11) In this locus, we identified four statistically independent genome-wide effects, three of which were found under the same association peak (Figure 2A ), illustrating how our approach and the large sample size clarifies associations described in smaller studies and can facilitate functional follow-up of complex loci.
We also performed a joint analysis of available data on sex chromosome variants (Supplementary Methods) and we identified rs2807267 as genome-wide significant (OR T =1.07, p-value=6.86x10 -9 ; Supplementary Tables 8-9 ). This variant lies within an enhancer peak specific for T cells and is 948bps downstream of the RNA U6 small nuclear 320 pseudogene (RNU6-320P), a component of the U6 snRNP (small nuclear ribonucleoprotein) that is part of the spliceosome and is responsible for the splicing of introns from pre-mRNA (12) ( Figure 2B ). The nearest gene is VGLL1 (27,486bps upstream) that has been proposed to be a co-activator of mammalian transcription factors.(13) No variant in the Y chromosome had a p-value lower than 0.05 in either the discovery or replication sets.
The MHC was the first MS susceptibility locus to be identified, and prior studies have found that it harbors multiple independent susceptibility variants, including interactions within the class II HLA genes. (14, 15) We undertook a detailed modeling of this region to account for its longrange linkage disequilibrium and allelic heterogeneity using SNP data as well as imputed classical alleles and amino acids of the human leukocyte antigen (HLA) genes in the assembled data. We confirm prior MHC susceptibility variants (including a non-classical HLA effect located in the TNFA/LST1 long haplotype) and we extend the association map to uncover a total of 31 statistically independent effects at the genome-wide level within the MHC (Figure 3 , Supplementary Table 10 ). An interesting finding is that several HLA and nearby non-HLA genes have several independent effects that can now be identified due to our large sample, e.g. the HLA-
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DRB1 locus has six statistically independent effects. Another exciting finding involves HLA-B that also appears to harbor 6 independent effects on MS susceptibility. Figure 2) . Second, we observe that there is a group of HLA*DQB1 and HLA*DQA1 SNPs, alleles, and amino acids that consistently rank amongst the best models with HLA-DRB1*15:01 interaction terms (Supplementary Figure 3) . This group of HLA-DRB1*15:01-interacting variants is consistently identified regardless of the marginal effects of other statistically independent variants that are added in the model, implying that these interaction terms capture a different subset of phenotypic variance and can be explored after the identification of the marginal effects.
Finally, we performed a sensitivity analysis by including interaction terms of HLA-DRB1*15:01 in each step and selecting the model with the lowest Bayesian information criterion (BIC), instead of testing only the marginal results of the variants as we did in the main analysis. This sensitivity analysis also resulted in 32 statistically independent effects with a genome-wide significant pvalue (Supplementary Table 11 ), of which one third (9 out of 32) were not effects in classical HLA genes. The main differences between the results of the two approaches were the inclusion of interaction of HLA-DRB1*15:01 and rs1049058 in step 3 and the stronger association of HLA*DPB1/2 effects over HLA*DRB1 effects in the sensitivity model (Supplementary Tables threshold of statistical significance (Supplementary Figure 4) . This provides additional circumstantial evidence that this category of variants may harbor true causal associations. On the other hand, the "NR" enrichment results seem to follow a rather random pattern, suggesting that most of these effects are indeed not truly MS-related (Supplementary Figure 4) .
The strong enrichment of the GW effects in immune cell types motivated us to prioritize candidate MS susceptibility genes by identifying those susceptibility variants, which affect RNA expression of nearby genes (cis expression quantitative trait loci effect, cis -eQTL) (±500Kbps around the effect SNP; Supplementary Methods). Thus, we interrogated the potential function of MS susceptibility variants in naive CD4+ T cells and monocytes from 415 healthy subjects as well as peripheral blood mononuclear cells (PBMCs) from 225 remitting relapsing MS subjects.
Thirty-six out of the 200 GW MS effects (18%) had at least one tagging SNP (r2>=0.5) that altered the expression of 46 genes (FDR<5%) in CD4+ naïve T cells (Supplementary Table 14) , and 36 MS effects (18%; 10 common with the CD4+ naïve T cells) influenced the expression of 48 genes in monocytes (11 genes in common with T cells). In MS PBMC, 30% of the GW effects (60 out of the 200) were cis-eQTLs for 92 genes in the PBMC MS samples, with several loci being shared with those found in healthy T cells and monocytes (26 effects and 27 genes in T cells, and 21 effects and 24 genes in monocytes, respectively; Supplementary Table 14) .
Since MS is a disease of the CNS, we also investigated a large collection of dorsolateral prefrontal cortex RNA sequencing profiles from two longitudinal cohort studies of aging (n=455), Table 15 ).
To further explore the challenging and critical question of whether some of the MS variants have an effect that is primarily exerted through a non-immune cell, we performed a secondary analysis of our cortical RNAseq data in which we attempted to ascribe a brain cis-eQTL to a particular cell type. Specifically, we assessed our tissue-level profile and adjusted each cis-eQTL analysis for the proportion of neurons, astrocytes, microglia, and oligodendrocytes estimated to be present in the tissue: the hypothesis was that the effect of a SNP with a cell type-specific ciseQTL would be stronger if we adjusted for the proportion of the target cell type ( Figure 6 ). As anticipated, almost all of the MS variants present in cortex remain ambiguous: it is likely that many of them influence gene function in multiple immune and non-immune cell types. However, the SLC12A5 locus is different: here, the effect of the SNP is significantly stronger when we account for the proportion of neurons ( Figure 6A and 6B), and the CLECL1 locus emerges when we account for the proportion of microglia. SLC12A5 is a potassium/chloride transporter that is known to be expressed in neurons, and a rare variant in SLC12A5 causes a form of pediatric epilepsy (26, 27 Table 18 ). These resultsalong with the results relating to microglia -emphasize the need for further dissection of these pathways in specific cell types to resolve where a variant is exerting its effect; it is possible that multiple, different cell types could be involved in disease since they all experience the effect of the variant.
Pathway and gene-set enrichment analyses can only identify statistically significant connections of genes in already reported, and in some cases validated, mechanisms of action.
However, the function of many genes is yet to be uncovered and, even for well-studied genes, the full repertoire of possible mechanisms is incomplete. To complement the pathway analysis approach and to explore the connectivity of our prioritized GW genes, we performed a proteinprotein interaction (PPI) analysis using GeNets (Supplementary Methods).(33) About a third of the 551 prioritized genes (n=190; 34.5%) were connected (p-value = 0.052) and these could be organized into 13 communities, i.e. sub-networks with higher connectivity (p-value: < 0.002;
Supplementary Even where a function is reported, further work is needed to demonstrate that the effect is the causal functional change. This is particularly true of the role of the CNS in MS susceptibility:
we mostly have data at the level of the human cortex, a complex tissue with many different cell types, including resident microglia and a small number of infiltrating macrophage and lymphocytes. MS variants clearly influence gene expression in this tissue, and we must now: (1) resolve the implicated cell types and whether pathways shared with immune cells are having their MS susceptibility effect in the periphery or in the brain and; (2) Step 1" plots the associations conditioning on rs11809700; rs12133753 is the most statistically significant SNP (OR C =1.14; pvalue= 8.53x10 -09 ). "
Step 2" plots the results conditioning on rs11809700 and rs12133753, with rs1415069 displaying the lowest p-value (OR G =1.10; p-value= 4.01x10 -5 ). Finally, "
Step 3" plots the associations conditioning on rs11809700, rs12133753, and rs1415069, identifying rs58394161 as the most-statistically significant SNP (OR C =1.10; p-value= 8.63x10 -4 ). All 4 SNPs reached genome-wide significance in the respective joint, discovery plus replication, analyses (Supplementary Table 6 
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SLC12A5 and CLECL1 are highlighted in red; in blue, we highlight a selected subset of the MS genes -many of them well-validated -which are enriched in microglia. For clarity, we did not include all of the MS genes that fall in this category.
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Supplementary Materials:
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